Premium
VEGF 165 b the anti‐angiogenic isoform of VEGF inhibits tumor growth in vivo .
Author(s) -
HamdollahZadeh Maryam,
Harper Steve,
Bates David
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.592.6
Subject(s) - bevacizumab , in vivo , medicine , angiogenesis , saline , vascular endothelial growth factor , colorectal cancer , cancer , chemistry , endocrinology , cancer research , chemotherapy , vegf receptors , biology , microbiology and biotechnology
To determine the potential of the anti‐angiogenic isoform,VEGF 165 b for cancer therapy, we compared the inhibitory effects of recombinant human VEGF 165 b on mouse model of colon cancer with bevacizumab. 2x10 6 LS174T human colon carcinoma cells were injected subcutaneously (SC) into the intrascapular dorsal region of nude mice. Tumor‐bearing mice were injected intraperitoneally (IP) with saline or bevacizumab (50 ?g), or SC in the lumbar region with 100 ?g VEGF 165 b bi‐weekly for 2 weeks. The inhibitory concentration of the IC 50 was calculated. Growth of tumors was significantly suppressed by SC VEGF 165 b injection compared to those treated by saline (p<0.001) or bevacizumab (p<0.001), which also significantly reduced tumor growth (p<0001, 2 way ANOVA). SC injection of VEGF 165 b resulted in a significant reduction of tumor volume from 254±51mm 3 to 35.4±17mm 3 after injection (p<0.01 compared with before treatment, rmANOVA, Dunnets), whereas bevacizumab stabilised tumor growth (231±22 before compared with 342.± 117mm 3 , NS). Tumors in saline treated mice grew significantly from 149±46 to 853±362mm 3 , (p<0.001). The IC 50 of VEGF 165 b was calculated to be 48µg. Administration of VEGF 165 b inhibits the growth of colon cancer in vivo and indicates that systemic therapy of VEGF 165 b may be an effective anti‐VEGF tool for the treatment of colon cancer. This work supported by AICR and PhiloGene Inc.